2026 ICD-10-CM Diagnosis Code Z16.21Resistance to vancomycin
Z16.21 is a billable ICD-10-CM diagnosis code for resistance to vancomycin. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 867 through 869. The code is not accepted as a principal diagnosis by the Medicare Code Editor. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Resistance to antimicrobial drugs.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for Z16.21.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Infection caused by Enterococcus
- Infection caused by glycopeptide intermediate Staphylococcus aureus
- Infection caused by glycopeptide intermediate/resistant Staphylococcus aureus
- Infection caused by glycopeptide resistant Staphylococcus aureus
- Infection caused by vancomycin intermediate Staphylococcus aureus
- Infection caused by vancomycin intermediate/resistant Staphylococcus aureus
- Infection caused by vancomycin resistant Enterococcus
- Infection caused by vancomycin resistant Staphylococcus aureus
- Infection caused by vancomycin resistant Staphylococcus aureus, coagulase positive
- Pneumonia caused by Enterococcus
- Pneumonia caused by vancomycin resistant Enterococcus
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- to
- vancomycin - Z16.21
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Resistance, resistant(to)
- organism (s)
- to
- drug
- vancomycin
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Convert Z16.21 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About Z16.21Overview
Is Z16.21 (Resistance to other antibiotics) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report resistance to vancomycin on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does Z16.21 group to?
On inpatient claims, resistance to vancomycin maps to MS-DRG 867, 868, 869, with relative weights from 0.7297 to 2.0932 depending on complications. Higher weights mean higher Medicare reimbursement.
Can Z16.21 be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because resistance to vancomycin describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
What is the ICD-9 equivalent of Z16.21?
Under the General Equivalence Mappings, resistance to vancomycin converts to ICD-9-CM V09.80 (inf mcr rst ot drg nt ml). The mapping is approximate, so confirm the match fits the documentation.
